Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 12:43 p.m.

    📋 IONIS PHARMACEUTICALS, INC. (IONS) - Clinical Trial Update

    Filing Date: 2022-07-11

    Accepted: 2022-07-11 10:14:22

    Event Type: Clinical Trial Update

    Event Details:

    Ionis Pharmaceuticals Inc (IONS) Announces Clinical Trial Update Ionis Pharmaceuticals Inc (IONS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients, treatments
    • Diseases/Conditions: a range of unmet medical needs, presentation at an upcoming medical meeting
    • Clinical Stage: NCT04014335, Phase 2 study
    • Collaboration: IgAN

    🔬 Clinical Development Pipeline (IONIS PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 Angelman Syndrome ClinicalTrials.gov
    ION582 DRUG Phase PHASE3 Angelman Syndrome ClinicalTrials.gov
    Sham procedure PROCEDURE Phase PHASE1 Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome ClinicalTrials.gov
    ION440 DRUG Phase PHASE1 Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ionis Pharmaceuticals Inc
    • CIK: 0000874015
    • Ticker Symbol: IONS
    • Period End Date: 2022-07-11
    • Document Type: 8-K

Search

News categories